A phase 2 clinical trial assessing the efficacy and safety of pembrolizumab and radiotherapy in patients with metastatic triple-negative breast cancer.

Alice Y HoChristopher A BarkerBrittany B ArnoldSimon N PowellZishuo I HuAyca GucalpLizza Lebron-ZapataHannah Y WenCindy KallmanAlessandro D'AgnoloZhigang ZhangJessica FlynnSamantha A DunnHeather L McArthur

Published in: Cancer (2019)

The combination of pembrolizumab and RT was found to be safe and demonstrated encouraging activity in patients with poor-prognosis, metastatic, triple-negative breast cancer who were unselected for programmed death-ligand 1 expression. Larger clinical trials of checkpoint blockade plus RT with predictive biomarkers of response are needed.

Keyphrases

poor prognosis
clinical trial
long non coding rna
advanced non small cell lung cancer
phase ii
dna damage
early stage
small cell lung cancer
squamous cell carcinoma
open label
double blind
cell cycle
locally advanced
study protocol
radiation therapy
radiation induced